Navigation For Mobile

Author Archives: Saharsh Davuluri

Small Pharma Steps Up

Here’s some good news, courtesy of DCAT Value Chain Insights: “Smaller bio/pharmaceutical companies are accounting for an increasingly larger portion of new products as measured by recent new molecular entity…

Posted in drug discovery, drugs, FDA | Tagged , , , , | Comments Off on Small Pharma Steps Up

Why You Need to Have the ‘Supply Chain’ Conversation with Your Pharma Suppliers

Supply chain security has been the subject of numerous posts on this blog in the past. It is important to note, however, that the pandemic hasn’t widely impacted global supply…

Posted in APIs, CMC, Contract Manufacturing, COVID19, supply chain | Tagged , , , | Comments Off on Why You Need to Have the ‘Supply Chain’ Conversation with Your Pharma Suppliers

Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

“Blockbuster” drugs — typically defined as those that generate annual sales of $1 billion or more — have been the lifeblood of Big Pharma company revenues since Smith, Kline and French’s…

Posted in blockbuster, drugs | Tagged , , , | Comments Off on Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

Atmanirbhar Bharat and PLI: A Future From the Past

It is difficult to discuss India’s ‘Make in India’ plan without reference to China, and any discussion of India-China relations ultimately leads to a political – rather than economic or…

Posted in India, outsourcing, supply chain | Tagged , , , , , | Comments Off on Atmanirbhar Bharat and PLI: A Future From the Past

Generic Drug Opportunities in Global Markets

Generic drugs have moved quickly over the last 30 years into a position of dominance in drug markets around the world. In 2018, generic drug savings totaled $293 billion in…

Posted in APIs, drugs, generic | Tagged , , | Comments Off on Generic Drug Opportunities in Global Markets

API Production: Building a Process Safety Culture

Working in the pharmaceutical manufacturing industry may bring many rewards, but it also has an element of risk. We often work alongside hazardous chemicals, in both labs and manufacturing spaces….

Posted in API synthesis, APIs, Capabilities, Chemistry, EHS, Neuland Labs, process chemistry, Process Engineering, safety | Tagged , , , | Comments Off on API Production: Building a Process Safety Culture

Earth Day 2021: Reinventing Business As Usual

April 22 is Earth Day and this year’s theme is Restore our Earth. On their website, Earthday.org states “When life around the globe returns to normal, our world cannot return…

Posted in atom economy, Chemistry, corporate stewardship, drugs, Effluent, EHS, energy conservation, energy effciency, green chemistry | Tagged , , , , | Comments Off on Earth Day 2021: Reinventing Business As Usual

The Dizzying Confusion of Drug Pricing Regulations

In 2019, drug pricing was expected to be a top drug industry issue heading into the New Year. Things changed in 2020. The pharma industry (and the whole world) was…well…slightly…

Posted in drugs, generic, Industry news, supply chain | Tagged , , | Comments Off on The Dizzying Confusion of Drug Pricing Regulations

Overcoming the Challenges of API Complexity

Pharmaceutical drug molecules are becoming increasingly complex, posing challenges in formulation development and manufacturing. This is particularly true of small molecule drug APIs and peptides, both of which have a…

Posted in API synthesis, APIs, atom economy, Chemistry, corporate stewardship, drugs, Effluent, EHS, energy conservation, energy effciency, green chemistry, Neuland Labs | Tagged , , , , | Comments Off on Overcoming the Challenges of API Complexity

Weighing the Potential for APIs and Finished Dosage Forms in Emerging Markets

New markets for drug manufacturers are emerging worldwide in regions that have typically purchased and imported drugs in finished dosage forms. While this shift has been underway for a few…

Posted in API synthesis, APIs, Chemistry, Contract Manufacturing, drugs, generic, Neuland Labs, supply chain | Tagged , , , , , | Comments Off on Weighing the Potential for APIs and Finished Dosage Forms in Emerging Markets